Physician profile
Gregory Pinto
NPI 1316082068
$3,716.74
in general payments reported to CMS, 2019-2025
21 companies · $405 in 2025
The $405 reported for 2025 was more than what 75% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $472 · 2020: $523 · 2021: $507 · 2022: $502 · 2023: $395 · 2024: $912 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,712.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $642.72 | 2022-2024 | Envista Mx60 Iol, Envista Aspire Iol, Ic-8 Apthera Iol |
| Alcon Vision LLC | $507.43 | 2022-2025 | Rocklatan, Eysuvis, Clareon |
| Aerie Pharmaceuticals, INC. | $317.67 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $280.13 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $229.71 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $212.60 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $196.29 | 2019-2025 | |
| Oyster Point Pharma, INC. | $195.19 | 2022-2024 | Tyrvaya, Ryzumvi |
| Kala Pharmaceuticals, INC. | $151.25 | 2019-2021 | |
| Horizon Therapeutics Plc | $124.99 | 2020 | |
| Amgen INC. | $124.99 | 2024 | Uplizna |
| Abbvie INC. | $124.92 | 2025 | |
| Shire North American Group INC | $123.21 | 2019 | |
| Omeros Corporation | $120.73 | 2021 | |
| Novo Nordisk INC | $116.80 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $84.94 | 2022 | |
| Janssen Pharmaceuticals, INC | $79.48 | 2019 | |
| Allergan, INC. | $29.66 | 2019-2021 | |
| Spark Therapeutics, INC. | $21.27 | 2022 | |
| Rayner Intraocular Lenses Limited | $17.86 | 2024 | Omidria, Rayone Aspheric, Rayone Emv |
| Ocular Therapeutix, INC. | $14.90 | 2023 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Pinto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.